ClinicalTrials.gg
RecruitingNCT06970990Updated May 22, 2025

Use of Nasal Pressure to Assess Inspiratory Effort Under Different Oxygen Treatments

An interventional study of HFNC:50L/min and HFNC:flow=40L/min in Critical Care and Inspiratory Effort, sponsored by Jian-Xin Zhou. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by Jian-Xin Zhou · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study was to investigate the effects of different oxygen therapy modalities (including nasal cannula oxygen, mask oxygen and high-flow nasal cannula oxygen) on the correlation between Nasal Pressure and Esophageal Pressure by means of a prospective physiological study, to assess the dynamic changes of nasal pressure and esophageal pressure and their underlying mechanisms under different conditions of oxygen therapy, to analyse the effects of oxygen therapy parameters on the relationship between the two, and to explore the feasibility of nasal pressure as a non-invasive monitoring indicator, in order to replaceor supplement esophageal manometry in clinical practice, especially in patients with respiratory distress and instability.Meanwhile, this study will also evaluate the effects of different oxygen therapy modalities on patients' respiratory mechanics and comfort, provide a scientific basis for the clinical selection of individualised oxygen therapy regimens, and ultimately provide new physiological evidence for the management of oxygen therapy in patients with acute respiratory failure in the intensive care unit (ICU) and outside the ICU, promote the development of non-invasive monitoring technology, and improve the clinical prognosis and therapeutic experience of patients.

Read the detailed description

Patients in the intensive care unit (ICU) often require different modalities of oxygen therapy to maintain adequate oxygenation.Common oxygen therapy modalities include nasal cannula oxygen, face mask oxygen and high flow nasal cannula oxygen (HFNC).These modalities of oxygen therapy not only affect the patient's oxygenation status, but may also influence nasal and esophageal pressures by altering the upper airway pressure gradient, which in turn affects respiratory mechanics and patient comfort.

Esophageal pressure fluctuations (ΔPes), as a reflection of mean transpulmonary pressure during unassisted voluntary breathing, provide an important basis for assessing inspiratory effort.However, esophageal manometry still faces many challenges for its bedside implementation in clinical practice, especially in unstable patients with respiratory distress and severely impaired gas exchange.Notably, the COVID-19 pandemic has led to a significant increase in the number of patients with acute respiratory failure, who often require condition-specific oxygen therapy of varying severity and are mostly treated outside the ICU.Given that such patients are at high risk of deterioration, it is particularly important to continuously monitor their inspiratory effort.

nasal pressure is an important physiological indicator for assessing upper airway resistance and airflow dynamics characteristics, whereas esophageal pressure is a key parameter that directly reflects intrathoracic pressure and respiratory effort.Previous studies have shown that there may be a physiological correlation between intranasal pressure and oesophageal pressure, and that this correlation may be influenced by a variety of factors, including airflow velocity, oxygen concentration, and the dynamics of upper airway resistance.Earlier physiological studies by comparing oesophageal pressure fluctuations (ΔPes) with nasal pressure fluctuations (ΔPnose) fluctuations found that when inspiratory effort was increased, there was no significant phase difference between these pressure waveforms.In addition, it was observed that there was a significant correlation between ΔPes and airway pressure fluctuations (ΔPaw) obtained by airway occlusion manoeuvres during inspiratory effort testing.However, although these findings provide important clues for understanding respiratory mechanics, studies on the correlation between nasal pressure and esophageal pressure under different oxygen therapy conditions are still relatively limited, especially lacking data support from prospective physiological studies.Therefore, further systematic studies are needed in the future to investigate in depth the effects of different oxygen therapy parameters (e.g., flow rate, humidity, and temperature, etc.) on the relationship between nasal pressure and esophageal pressure, so as to provide more precise guidance for clinical practice.

02

Conditions studied

  • Critical Care
  • Inspiratory Effort

Keywords

  • Esophageal pressure
  • inspiratory effort
  • oxygen treatments
  • Nasal Pressure
03

In context

Lead sponsor

Jian-Xin Zhou is the lead sponsor of 11 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. No mechanical ventilation required,Able to tolerate oxygen therapy via nasal cannula, standard face mask, or nasal high-flow oxygen therapy;
  2. Respiratory stability:Capable of spontaneous breathing with effective cough for secretion clearance.Oxygen saturation (SpO₂) > 90% or PaO₂/FiO₂ ≥ 150 mmHg when receiving nasal cannula oxygen at 3 L/min;
  3. Hemodynamic stability:Heart rate (HR) ≤ 120 bpm;Systolic blood pressure (SBP) 90-150 mmHg;No vasoactive medications OR norepinephrine dosage \< 0.1-0.2 μg/kg·min (or equivalent doses of other vasoactive agents);
  4. Metabolic stability;
  5. Compliance with medical instructions.Able to follow prescribed tasks.Esophageal pressure monitoring catheter already in place;
  6. Patient or legal guardian agrees to participate and has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years;
  2. Pregnancy;
  3. Hemodynamic instability:Mean arterial pressure (MAP) \< 60 mmHg.Heart rate (HR) > 120 bpm or \< 60 bpm;
  4. Respiratory instability:Respiratory rate (RR) > 35 bpm.Oxygen saturation (SpO₂) \< 90%;
  5. Neuromuscular diseases or phrenic nerve injury;
  6. Recent trauma or surgery involving the trachea, esophagus, neck, or chest. to esophageal catheter placement or inability to monitor esophageal pressure;
  7. Nasal obstruction or anatomical abnormalities:Complete nasal obstruction.Severe anatomical abnormalities (e.g., severe septal deviation, nasal polyps, or tumors) preventing catheter placement or compromising ventilation;
  8. High-risk craniofacial conditions:Severe facial trauma or skull base fracture with risk of catheter misplacement into the intracranial space.Active epistaxis or incomplete healing after nasal surgery;
  9. Bleeding risk:Severe coagulopathy.Esophageal/gastric varices or other conditions predisposing to hemorrhage.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    HFNC:flow=50L/min

    Under high-flow oxygen therapy at a flow rate of 50 L/min, record/monitor for 5 minutes

    Procedure: HFNC:50L/min

  • Experimental
    HFNC:flow=40L/min

    Under high-flow oxygen therapy at a flow rate of 40 L/min, record/monitor for 5 minutes

    Procedure: HFNC:flow=40L/min

  • Experimental
    HFNC:flow=30L/min

    Under high-flow oxygen therapy at a flow rate of 30 L/min, record/monitor for 5 minutes

    Procedure: HFNC:flow=30L/min

  • Experimental
    Face Mask Oxygen:8L/min

    Under face mask oxygen at a flow rate of 8 L/min, record/monitor for 5 minutes.

    Procedure: Face mask oxygen:8L/min

  • Experimental
    Face Mask Oxygen:5L/min

    Under face mask oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.

    Procedure: Face mask oxygen:5L/min

  • Experimental
    Nasal cannula oxygen:5L/min

    Under nasal cannula oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.

    Procedure: Nasal cannula oxygen:5L/min

  • Experimental
    Nasal cannula oxygen:3L/min

    Under nasal cannula oxygen at a flow rate of 3 L/min, record/monitor for 5 minutes.

    Procedure: Nasal cannula oxygen:3L/min

Interventions

  • ProcedureHFNC:50L/min

    Under high-flow oxygen therapy at a flow rate of 50 L/min, record/monitor for 5 minutes

  • ProcedureHFNC:flow=40L/min

    Under high-flow oxygen therapy at a flow rate of 40 L/min, record/monitor for 5 minutes.

  • ProcedureHFNC:flow=30L/min

    Under high-flow oxygen therapy at a flow rate of 30 L/min, record/monitor for 5 minutes.

  • ProcedureFace mask oxygen:8L/min

    Under face mask oxygen at a flow rate of 8 L/min, record/monitor for 5 minutes.

  • ProcedureFace mask oxygen:5L/min

    Under face mask oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.

  • ProcedureNasal cannula oxygen:5L/min

    Under nasal cannula oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.

  • ProcedureNasal cannula oxygen:3L/min

    Under nasal cannula oxygen at a flow rate of 3 L/min, record/monitor for 5 minutes.

06

What researchers measure

Primary outcomes

  1. Tidal swing of nasal cuff pressure (ΔPnose)

    Tidal swing of nasal pressure (ΔPnose) will be measured

    Time frame: From enrollment to the end of treatment at 4 hours

  2. Tidal swing of esophageal pressure (∆Pes)

    Tidal swing of esophageal pressure (∆Pes) will be measured

    Time frame: From enrollment to the end of treatment at 4 hours

Secondary outcomes

  1. Respiratory rate

    Respiratory rate will be measured at each type of oxygen treatment.

    Time frame: From enrollment to the end of treatment at 4 hours.

  2. COMFORT scale

    COMFORT scale will be measured

    Time frame: From enrollment to the end of treatment at 4 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Nov 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 14, 2025
StartActual
May 20, 2025
Primary completionEst.
Nov 30, 2025
CompletionEst.
Dec 30, 2025
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970990
Lead sponsor
Jian-Xin Zhou
Responsible party
Jian-Xin Zhou (Head of Emergency and Critical Care Center, Capital Medical University) — Sponsor-investigator
First posted
May 14, 2025
Start date
May 20, 2025
Primary completion
Nov 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
May 22, 2025

Study contacts

Jian-Xin Zhou, MD, PhD
Contact
zhoujx.cn@icloud.com
8610 6392 6666
Rui-Zhi Zhang,MD
Contact
ifz0000@126.com
Jian-Xin Zhou, MD, PhD
principal investigator · Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion